Douglas Fambrough

Douglas Fambrough is a seasoned biotechnology executive with extensive experience in both management and investment within the field. Currently serving as Managing Partner at KCap Biotechnology Fund LP since June 2023, Fambrough also holds board member positions at Switch Therapeutics, Sirius Therapeutics, and Anjarium Biosciences, contributing to the development of innovative therapeutic technologies. Previously, Fambrough was the Founder, President, and CEO of Dicerna Pharmaceuticals, a publicly traded company acquired by Novo Nordisk for $3.3 billion in 2021. Fambrough's career began at Oxford Bioscience Partners, progressing from Associate to General Partner, and includes significant research experience as a Post-doctoral Fellow at the Whitehead Institute. Fambrough earned a PhD in Genetics from the University of California, Berkeley, and an AB in Biology from Cornell University.